Ewing's sarcoma treatment in Scandinavia 1984-1990--ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV
(1998) In Acta Oncologica 37(4). p.375-378- Abstract
- A report on the long-term follow up of the first cooperative Scandinavian Sarcoma Group study in Ewing's sarcoma of bone is presented. Fifty-two previously untreated patients entered the study between 1984 and 1990. Half of the tumors were located in the extremities and one quarter in the pelvis. The combined modality treatment consisted of 5 cycles of chemotherapy--including vincristine, methotrexate, doxorubicin, cyclophosphamide, bleomycin and dactinomycin. The first two cycles were followed by local resection or amputation in 35 patients and by radiotherapy alone in 17 patients. When surgery was not performed, was incomplete or yielded poor margins radiotherapy was given at a dose of 40-60 Gy. Local tumor relapses developed in 10... (More)
- A report on the long-term follow up of the first cooperative Scandinavian Sarcoma Group study in Ewing's sarcoma of bone is presented. Fifty-two previously untreated patients entered the study between 1984 and 1990. Half of the tumors were located in the extremities and one quarter in the pelvis. The combined modality treatment consisted of 5 cycles of chemotherapy--including vincristine, methotrexate, doxorubicin, cyclophosphamide, bleomycin and dactinomycin. The first two cycles were followed by local resection or amputation in 35 patients and by radiotherapy alone in 17 patients. When surgery was not performed, was incomplete or yielded poor margins radiotherapy was given at a dose of 40-60 Gy. Local tumor relapses developed in 10 patients and in all but one patient were accompanied by metastatic disease. Five patients had metastasis at diagnosis and distant metastases developed after primary treatment in 27 patients after a median of 14 months. The median follow-up time for the 20 surviving patients is 10 years. At 5 years the tumor-related survival was 46% and the metastasis-free survival 43%. Late tumor relapses occurred in 4 patients, which reduced the 10-year tumor related survival to 41% and the metastasis-free survival to 38%. Histopathological tumour response correlated with survival with 5-year metastasis-free survival rates of 73% for the good responders and 35% for the poor responders. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1113461
- author
- Nilbert, Mef LU ; Saeter, G ; Elomaa, I ; Monge, O R ; Wiebe, Thomas LU and Alvegard, T A
- organization
- publishing date
- 1998
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Acta Oncologica
- volume
- 37
- issue
- 4
- pages
- 375 - 378
- publisher
- Taylor & Francis
- external identifiers
-
- pmid:9743460
- scopus:0031881054
- ISSN
- 1651-226X
- language
- English
- LU publication?
- yes
- id
- cd4ba8dc-b548-4d36-8178-73b7666ccd4f (old id 1113461)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/9743460
- http://informahealthcare.com/doi/abs/10.1080/028418698430601
- date added to LUP
- 2016-04-01 16:53:54
- date last changed
- 2022-01-28 22:55:45
@article{cd4ba8dc-b548-4d36-8178-73b7666ccd4f,
abstract = {{A report on the long-term follow up of the first cooperative Scandinavian Sarcoma Group study in Ewing's sarcoma of bone is presented. Fifty-two previously untreated patients entered the study between 1984 and 1990. Half of the tumors were located in the extremities and one quarter in the pelvis. The combined modality treatment consisted of 5 cycles of chemotherapy--including vincristine, methotrexate, doxorubicin, cyclophosphamide, bleomycin and dactinomycin. The first two cycles were followed by local resection or amputation in 35 patients and by radiotherapy alone in 17 patients. When surgery was not performed, was incomplete or yielded poor margins radiotherapy was given at a dose of 40-60 Gy. Local tumor relapses developed in 10 patients and in all but one patient were accompanied by metastatic disease. Five patients had metastasis at diagnosis and distant metastases developed after primary treatment in 27 patients after a median of 14 months. The median follow-up time for the 20 surviving patients is 10 years. At 5 years the tumor-related survival was 46% and the metastasis-free survival 43%. Late tumor relapses occurred in 4 patients, which reduced the 10-year tumor related survival to 41% and the metastasis-free survival to 38%. Histopathological tumour response correlated with survival with 5-year metastasis-free survival rates of 73% for the good responders and 35% for the poor responders.}},
author = {{Nilbert, Mef and Saeter, G and Elomaa, I and Monge, O R and Wiebe, Thomas and Alvegard, T A}},
issn = {{1651-226X}},
language = {{eng}},
number = {{4}},
pages = {{375--378}},
publisher = {{Taylor & Francis}},
series = {{Acta Oncologica}},
title = {{Ewing's sarcoma treatment in Scandinavia 1984-1990--ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV}},
url = {{http://www.ncbi.nlm.nih.gov/pubmed/9743460}},
volume = {{37}},
year = {{1998}},
}